Roche Has Eylea In Its Sights After Farcimab Approval
FDA Backs First Bispecific Antibody For The Eye
Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market.
You may also be interested in...
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.